Previous 10 | Next 10 |
Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021 U.S. End User Demand up 45% vs. Second Quarter of 2021 International Segment End User Demand Up 21% vs. Second Quarter of 2021 ATLANTA, July 27, 2022 (GLOBE NEWSWIRE...
Alimera Sciences ( NASDAQ: ALIM ): Q2 For further details see: Alimera Sciences reports Q2 results
ADP , AEP , ALIM , ALKS , APH , ASC , ATOS , AVY , BA , OTCQX:BASFY , BG , BMY , BSX , BXMT , CAMT , CCJ , CHEF , CME , COOP , CPG , CS , CSTM , OTCQX:DANOY , DB , EDU , EQNR , EVR ...
ATLANTA, July 26, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will...
Alimera Sciences ( NASDAQ: ALIM ) on Friday said it would launch its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in France through its distribution partner Horus Pharma. ALIM said Horus had been granted pricing and reimbursement approval...
ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces th...
ATLANTA, July 13, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
Alimera Sciences ( NASDAQ: ALIM ) has got Italian regulatory approval for its Iluvien injection for the treatment of uveitis, a form of eye inflammation. ALIM's Ireland-based European unit, Alimera Sciences Europe, got an approval and was granted pricing and reimbursement ...
ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces th...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
ATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will repo...
ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better...
ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that th...